Invivyd stock maintains Buy rating at BTIG, $10 target

BTIG maintained a Buy rating and $10.00 price target on Invivyd Inc. (NASDAQ:IVVD), citing upcoming immunogenicity data from the DECLARATION trial. The stock is trading at $0.56, down 76% year-to-date. The company reported positive results from the LIBERTY trial for VYD2311, with strong safety and tolerability compared to an mRNA vaccine. Invivyd has a 92% gross profit margin but is burning through cash quickly.

Original reporting
Published Nov 16, 2026, 4:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 4:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$IVVD
Bullish
medium confidence
Mentioned
$IVVD
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IVVDBullishLow
01

Why it matters

The main tradable element is sentiment around an upcoming immunogenicity dataset and the FDA-refined Accelerated Approval framework, but the lack of a specific date and absence of a new event update reduce immediacy.

02

Market read

Traders may use this as a sentiment and catalyst-timing check for IVVD, but it is not a fresh clinical outcome or regulatory decision.

03

What to watch

Cash burn is highlighted as a critical consideration, which can dominate valuation even if trial data timing improves; also, the FDA timing refinement is process-related rather than a confirmed clinical outcome.

Relevance 4/10Novelty 4/10Timing: imminent immunogenicity data for DECLARATION, but no specific date provided

Background

Invivyd is developing VYD2311 and running the expanded Phase 3 DECLARATION confirmatory trial, with an Accelerated Approval approach discussed with the FDA.

Company-level read

Ticker impact

$IVVDBullishMedium confidence
Context

BTIG maintained a Buy on Invivyd and reiterated a $10 target, citing imminent immunogenicity data from the DECLARATION trial and FDA dialogue on VYD2311’s Accelerated Approval path.

Expected impact

Likely modest support for the stock as traders price in the near-term possibility of confirmatory-conversion evidence, tempered by the lack of a specific data date.

Evidence & confidence

The piece is primarily an analyst stance, but it adds a concrete timing refinement (FDA dialogue) and reiterates the $10 target, which can influence near-term sentiment around trial catalysts.

Market effects

Reinforces investor focus on COVID-era monoclonal antibody development and Accelerated Approval conversion pathways for biotech trial programs.

Limited, single-name biotech sentiment with no clear broader regional catalyst.

Low, as the story is company-specific and tied to US FDA process and trial execution.

Counterpoint

The article provides no new trial event update and no specific immunogenicity data date, so the catalyst may slip and the stock’s extreme YTD drawdown could reflect deeper execution or financing risk.

Key entities

  • Invivyd Inc.

    NASDAQ-listed biotech developing VYD2311 and running the DECLARATION trial; subject of the analyst rating and trial-timing commentary.

  • BTIG

    Maintained a Buy rating and $10 price target, citing imminent immunogenicity data and FDA dialogue.

  • FDA

    Dialogue with the FDA refined details of the Accelerated Approval approach for VYD2311.

Related articles

$IVVDMed

Invivyd Posts Wider Loss In Q3 As Operating Expenses Rise

Invivyd, Inc. (IVVD) reported a wider Q3 net loss of $33.47 million, up from $10.47 million YoY, due to higher operating expenses. Revenue rose 18% to $15.45 million. The company provided updates on its pipeline, including VYD2311 for COVID-19 and VMS063 for measles, and announced leadership changes. Cash reserves totaled $126.40 million.

$IVVDHigh

Invivyd Reports Third Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights • DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communic

$IVVDMedAI 8/10

Invivyd presents preclinical data on measles antibody candidate

Invivyd (NASDAQ:IVVD) presented preclinical data for its measles antibody candidate VMS063 at IDWeek 2026, showing antiviral activity against measles virus variants. The company plans to scale up manufacturing for clinical development in 2027. There are currently no FDA-approved treatments for measles, with U.S. cases nearly double in 2026 compared to 2025, according to Invivyd.

$IVVDLow

Invivyd, Inc. (IVVD) Unveils Preclinical Data for Measles mAb VMS063

Invivyd, Inc. (IVVD) presented preclinical data for VMS063, a novel monoclonal antibody for measles, showing in vitro activity against contemporary virus variants. The company is scaling up production for clinical development in 2027. There are currently no FDA-approved treatments for measles, and the U.S. is experiencing a surge in cases.

$IVVDLowAI 8/10

More than 9 million U.S. children are estimated to lack measles protection. Lab tests found an antibody could fight measles.

Invivyd (Nasdaq: IVVD) presented preclinical data for VMS063, a monoclonal antibody candidate for measles treatment and prevention. VMS063 showed potent in vitro activity against measles virus variants. Invivyd plans to scale up production for clinical development in 2027. The U.S. is experiencing a record number of measles cases in 2026, with over 9 million children unprotected.